Compared to patients in the L-immunity group, patients in the H-immunity group had an advanced American Joint Committee on Cancer (AJCC) stage, advanced T classification, lymph node metastasis, higher tall-cell PTC and lower follicular PTC proportions, more BRAF mutations and fewer RAS mutations. The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.